Dr. Maya Ghoussaini completed a PhD degree in Molecular Genetics at the Pasteur Institute of Lille, France, working on the genetic susceptibility of childhood obesity and Type 2 diabetes. In 2007, she moved to the Department of Oncology at the University of Cambridge where her research focussed on the genetic susceptibility of cancer (mainly breast) through the conduction of Genome Wide Association Studies and the identification of genetic variants that increase the risk of breast cancer. In 2014, Dr. Ghoussaini moved to the Queensland Institute of Medical Research in Brisbane, Australia to study chromatin conformation structure at cancer-associated loci and identify cancer-gene targets. She then moved to the Department of Pharmacology at the University of Cambridge where she used genome editing (CRISPR/Cas9) to understand how and why genetic variants can impact cancer cell behaviour and affect target gene expression. Since April 2017, Dr. Ghoussaini joined the Wellcome Trust Sanger Institute as Genetic Analysis Team Leader within the Open Targets consortium. This consortium integrates large-scale genetics and genomics data together with drug information to influence the way drug targets are identified and validated. Dr. Ghoussaini is also a Course Director and a tutor for the Undergraduate Certificate in Genetics at the University of Cambridge.